Results 11 to 20 of about 2,290 (211)

SARS-CoV-2 and diabetes: A potential therapeutic effect of dipeptidyl peptidase 4 inhibitors in diabetic patients diagnosed with COVID-19

open access: yesMetabolism Open, 2021
COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 and has become an urgent economic and health challenge. Dipeptidyl peptidase 4 (DPP4), also mentioned as a cluster of differentiation 26 (CD26) is a serine exopeptidase found in two ...
Zemene Demelash Kifle   +2 more
doaj   +1 more source

Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors [PDF]

open access: yesDiabetes & Metabolism Journal, 2022
Background It is not known which type 2 diabetes mellitus (T2DM) patients would most benefit from dipeptidyl peptidase-4 (DPP-4) inhibitor treatment.
Sangmo Hong   +3 more
doaj   +1 more source

DPP4 (dipeptidyl-peptidase 4) [PDF]

open access: yesAtlas of Genetics and Cytogenetics in Oncology and Haematology, 2013
Review on DPP4 (dipeptidyl-peptidase 4), with data on DNA, on the protein encoded, and where the gene is implicated.
Ohnuma, K, Morimoto, C
openaire   +2 more sources

Comparing treatment intensification and clinical outcomes of metformin and dipeptidyl peptidase‐4 inhibitors in treatment‐naïve patients with type 2 diabetes in Japan

open access: yesJournal of Diabetes Investigation, 2020
Japan's guidelines emphasize tailored therapy, but do not guide physicians on the use of a specific regimen in drug‐naive patients. The role of long‐term initial therapy could be important in key elements of diabetes treatment, such as continuation of ...
Takeshi Horii   +3 more
doaj   +1 more source

The role of dipeptidyl peptidase-4 inhibitors

open access: yesBMJ, 2012
Will be clearer once ongoing trials are complete Type 2 diabetes is a progressive disease and greater treatment intensity is needed over time to control increasingly abnormal glucose concentrations.1 In the linked article (doi:10.1136/bmj.e1369), Karagiannis and colleagues present a systematic review and meta-analysis of the risks and benefits ...
Lasserson, D, Mant, J
openaire   +4 more sources

The role of Dipeptidyl Peptidase‐4 in cutaneous disease [PDF]

open access: yesExperimental Dermatology, 2020
AbstractDipeptidyl peptidase‐4 (DPP4) is a multifunctional, transmembrane glycoprotein present on the cell surface of various tissues. It is present in multiple molecular forms including cell surface and soluble. The role of DPP4 and its inhibition in cutaneous dermatoses have been a recent point of investigation.
Payal M. Patel   +3 more
openaire   +2 more sources

The role of dipeptidyl peptidase 4 in hematopoiesis and transplantation [PDF]

open access: yesCurrent Opinion in Hematology, 2013
Dipeptidyl peptidase 4 (DPP4, CD26) is a protease that cleaves selected amino acids at the N-terminal penultimate position and has the potential to alter the protein function. The regulation and roles of DPP4 activity are not well understood; therefore, the purpose of this review is to discuss the recent literature regarding DPP4 regulation, as well as
Heather, O'Leary   +2 more
openaire   +2 more sources

An updated systematic review and meta-analysis on the efficacy and tolerability of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes with moderate to severe chronic kidney disease

open access: yesSAGE Open Medicine, 2016
Objective: This updated meta-analysis determines the effect of dipeptidyl peptidase-4 inhibitors on glycemic and tolerability outcomes in patients with type 2 diabetes mellitus and chronic kidney disease with glomerular filtration rate of ⩽60 mL/min or ...
Devada Singh-Franco   +2 more
doaj   +1 more source

The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study

open access: yesBMC Endocrine Disorders, 2021
Background Bullous pemphigoid is the most common bullous chronic autoimmune skin disease. Recent studies have suggested dipeptidyl-peptidase 4 inhibitors as possible predisposing agents of bullous pemphigoid.
Vaia Lambadiari   +10 more
doaj   +1 more source

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors [PDF]

open access: yesBioMed Research International, 2014
A cell surface serine protease, dipeptidyl peptidase 4 (DPP-4), cleaves dipeptide from peptides containing proline or alanine in the N-terminal penultimate position. Two important incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), enhance meal-stimulated insulin secretion from pancreaticβ-cells, but ...
Kim, Na-Hyung, Yu, Taeyang, Lee, Dae Ho
openaire   +2 more sources

Home - About - Disclaimer - Privacy